Diagnostic Biomarkers and Therapeutic Targets of ALT-Positive Cancers

Abstract

Inside Precision MedicineVol. 9, No. 5 FeaturesDiagnostic Biomarkers and Therapeutic Targets of ALT-Positive CancersManrose Singh, Danny MacKenzie, Sanket Desai, Noelle Batista, and Dong ZhangManrose SinghSearch for more papers by this author, Danny MacKenzieSearch for more papers by this author, Sanket DesaiSearch for more papers by this author, Noelle BatistaSearch for more papers by this author, and Dong ZhangDong Zhang, PhD, is an associate professor of cancer biology and the director of Center for Cancer Research at the College of Osteopathic Medicine, New York Institute of Technology (NYIT). Dr. Zhang is also the founder and CSO of ALT Therapeutics, a biotech company dedicated to develop drugs targeting the ALT cancers, which include some of the most deadly cancers, such as glioblastoma and pancreatic cancers. Previously, Dr. Zhang worked at Wyeth Pharmaceutical and Pfizer Pharmaceutical as a staff scientist. Dr. Zhang is also an associate editor of Animal Model and Experimental Medicine.Search for more papers by this authorPublished Online:22 Oct 2022https://doi.org/10.1089/ipm.09.05.13AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 9Issue 5Oct 2022 InformationCopyright © GEN PublishingTo cite this article:Manrose Singh, Danny MacKenzie, Sanket Desai, Noelle Batista, and Dong Zhang.Diagnostic Biomarkers and Therapeutic Targets of ALT-Positive Cancers.Inside Precision Medicine.Oct 2022.48-50.http://doi.org/10.1089/ipm.09.05.13Published in Volume: 9 Issue 5: October 22, 2022PDF download